AU2001275438A1 - Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof - Google Patents

Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Info

Publication number
AU2001275438A1
AU2001275438A1 AU2001275438A AU7543801A AU2001275438A1 AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1 AU 2001275438 A AU2001275438 A AU 2001275438A AU 7543801 A AU7543801 A AU 7543801A AU 2001275438 A1 AU2001275438 A1 AU 2001275438A1
Authority
AU
Australia
Prior art keywords
proteins
fixed
viral capsid
stable
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001275438A
Inventor
Robert Garcea
C. Richard Schlegel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of AU2001275438A1 publication Critical patent/AU2001275438A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Novel acetone- or alcohol-fixed viral capsid proteins, bacteria-containing, and papillomavirus L1-GST fusion proteins are described. These proteins are useful in vaccine preparation and as diagnostics.
AU2001275438A 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof Abandoned AU2001275438A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21652600P 2000-07-06 2000-07-06
US60/216,526 2000-07-06
PCT/US2001/018701 WO2002004007A2 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
AU2001275438A1 true AU2001275438A1 (en) 2002-01-21

Family

ID=22807390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001275438A Abandoned AU2001275438A1 (en) 2000-07-06 2001-06-11 Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof

Country Status (7)

Country Link
US (1) US7279306B2 (en)
EP (1) EP1305039B1 (en)
AT (1) ATE418997T1 (en)
AU (1) AU2001275438A1 (en)
DE (1) DE60137230D1 (en)
ES (1) ES2317910T3 (en)
WO (1) WO2002004007A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ES2431963T3 (en) 2002-07-05 2013-11-28 Folia Biotech Inc. Adjuvant Viral Particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
JP2008511405A (en) 2004-08-30 2008-04-17 アリーン、ネビル Methods of using grafts for treatment of ligaments and tendons
CA2578113A1 (en) 2004-08-30 2006-03-09 Spineovations, Inc. Method of treating spinal internal disk derangement
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AT503690A1 (en) 2006-06-09 2007-12-15 Biomay Ag HYPOALLERGENIC MOLECULES
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
EP2078086A4 (en) 2006-11-15 2010-06-30 Folia Biotech Inc Immunogenic affinity-conjugated antigen systems based on papaya mosaic virus and uses thereof
WO2009055491A2 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
US8469961B2 (en) 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
US20120045479A1 (en) * 2008-10-17 2012-02-23 Sievers Robert E Dry Powder Formulations, Vaccines and Methods
EP2427763A4 (en) 2009-05-07 2013-08-21 Oncohealth Corp Identification of high grade or cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
EP2521914A4 (en) 2010-01-08 2013-07-10 Oncohealth Corp High throughput cell-based hpv immunoassays for diagnosis and screening of hpv-associated cancers
CN111000991B (en) * 2019-12-20 2023-04-21 浙江普康生物技术股份有限公司 Coxsackie virus A group 6 recombinant subunit protein vaccine and preparation method thereof
CN112472821B (en) * 2020-11-19 2022-11-18 北京大学 Application of protein nanoparticles in preparation of VSV (VSV virus) resistant product

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5475099A (en) * 1990-08-15 1995-12-12 Calgene Inc. Plant fatty acid synthases
US6071716A (en) * 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US5942607A (en) * 1993-07-26 1999-08-24 Dana-Farber Cancer Institute B7-2: a CTLA4/CD28 ligand
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
ES2264563T3 (en) * 1994-10-07 2007-01-01 Loyola University Of Chicago PARTICLES SIMILAR TO THE PAPILOMA VIRUS, FUSION PROTEINS AND PROCEDURE FOR PREPARATION.
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US5874089A (en) * 1995-10-02 1999-02-23 Georgetown University School Of Medicine Protecting against canine oral papillomavirus (copy)
DE122007000015I2 (en) * 1997-09-05 2008-01-24 Medimmune Inc Method for in vitro disassembly and reassembly of papillomavirus virus-like particles (vlps)
WO2000050447A1 (en) * 1999-02-24 2000-08-31 Acorda Therapeutics Carbohydrate epitope mimic peptides and uses thereof
US6551597B1 (en) * 1999-03-18 2003-04-22 President & Fellows Of Harvard College Vaccine compositions for human papillomavirus
DE19925199A1 (en) * 1999-06-01 2000-12-07 Medigene Ag Cytotoxic T cell epitopes of the papillomavirus L1 protein and their use in diagnostics and therapy

Also Published As

Publication number Publication date
WO2002004007A3 (en) 2002-04-18
WO2002004007A2 (en) 2002-01-17
EP1305039B1 (en) 2008-12-31
ES2317910T3 (en) 2009-05-01
ATE418997T1 (en) 2009-01-15
EP1305039A2 (en) 2003-05-02
US7279306B2 (en) 2007-10-09
US20070212374A1 (en) 2007-09-13
WO2002004007A9 (en) 2002-10-10
DE60137230D1 (en) 2009-02-12

Similar Documents

Publication Publication Date Title
AU2001275438A1 (en) Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
TR200001842T2 (en) Papilloma virus capsomer vaccine formulations- methods of use.
WO1999033868A3 (en) Human papillomavirus vaccine
DE69535018D1 (en) PAPILLOMA VIRUS VACCINE
MXPA02005639A (en) Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions.
AU2001236042A1 (en) Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell
UA85536C2 (en) Viral antigens
AU7545801A (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
WO2003068804A3 (en) Novel insect cell line
DE60037450D1 (en) FUNF-HELIX PROTEIN
MXPA02007478A (en) Human immunodeficiency virus vaccine.
AU2002228650A1 (en) Gas dehydration using membrane and potassium formate solution
WO2004101598A3 (en) Insertion of furin protease cleavage sites in membrane proteins and uses thereof
TW200505501A (en) CCI-779 lyophilized formulations
AU5137800A (en) Cd4-independent hiv envelope proteins as vaccines and therapeutics
CY1107431T1 (en) PARTICLES FOR GONAL TREATMENT
MXPA02012593A (en) Bvdv virus-like particles.
EP0957936A4 (en) Formulations of recombinant papillomavirus vaccines
AU5460900A (en) Infectious cdna clone of gb virus b and uses thereof
MXPA02003328A (en) Vaccine.
GB2379446A (en) Cells,culture methods and their uses
EP1309342A4 (en) Production of chimeric human papillomavirus
AP1561A (en) Use of non-cytolytic retrovirus as vaccines for the treatment of HIV infection.
AU4088299A (en) Novel post-transcriptional regulatory elements and uses thereof
DE69728447D1 (en) CHANGED SMALL RNA VIRUSES